Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Roy Chemaly

Roy F. Chemaly MD, MPH

Professor of Medicine, Department of Infectious Diseases, Infection Control, and Employee Health; Chief Infection Control Officer and Director, Clinical Virology Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas

Roy Chemaly, MD, MPH, CMQ, Professor, is Chief Infection Control Officer and Director of the Clinical Virology Research program. Dr. Chemaly’s interest include studies on the epidemiology, severity, prognosis, prevention and treatment of respiratory viral infections in immunocompromised cancer patients as well in the prevention of health care associated infections. Dr. Chemaly conducts clinical trials for the management and prevention of viral infections in cancer patients, Hematopoietic Cell Transplant (HCT) recipients, in particular, as well as on the composition of the upper respiratory tract microbiome as a risk factor for lower respiratory tract infections. He is also conducting clinical trials using CMV specific immuno-assays to predict CMV reactivation or progression. In addition, Dr. Chemaly and his lab team are conducting studies on whole genome sequencing for VRE, phages, and CMV to establish the transmission networks and the resistance and virulence genes associated with worse outcomes, respectively. His work in viral infections in HCT recipients has led to landmark publications in high impact journals like New England Journal of Medicine, Annals of Internal Medicine, Blood, and Clinical Infectious Diseases. He is the founder and past chair of the Transplant Infectious Diseases Special Interest Group of the American Society of Bone Marrow Transplantation and a member of the writing committee of the ASBMT guidelines for transplant infectious diseases, and the European Committee for Infections in Leukemia (ECIL 8). He is the co-chair of the Infection & Immune Reconstitution Working Committee of the ASTCT/CIBMTR, an executive member on the council for the International Immunocompromised Host Society (ICHS), and the scientific officer for the working group on respiratory viruses (ESGREV) of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID). Funding sources: NCI/NIH, NIH subcontracts, Private industry, Institutional Awards.


Dr. Chemaly has no relevant disclosures.